JORVEZA: A Non-halogenated Glucocorticosteroid Which Acts Primarily Anti-inflammatory Via Binding to the Glucocorticoid Receptor – Drug Insight and Market Forecasts, 2019-2022 and 2023-2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “JORVEZA Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about JORVEZA for Eosinophilic esophagitis (EoE) in the seven major markets. A detailed picture of the JORVEZA for EoE in the 5MM, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the JORVEZA for EoE.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JORVEZA market forecast analysis for EoE in the 5MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in EoE.

Drug Summary

Budesonide is a non-halogenated glucocorticosteroid, which acts primarily anti-inflammatory via binding to the glucocorticoid receptor. In treating EoE with JORVEZA, budesonide inhibits the antigen-stimulated secretion of many pro-inflammatory signal molecules such as thymic stromal lymphopoietin, IL-13, and eotaxin-3 in the esophageal epithelium, which results in a significant reduction of the esophageal eosinophilic inflammatory infiltrate.

The efficacy and safety of JORVEZA were evaluated for the induction of clinicopathological remission of EoE in adults in pivotal clinical studies EOS-1 and EOS-2. Additionally, the EMA granted ODD to budesonide for the treatment of EoE. The recommended daily dose is 2 mg budesonide as one 1 mg tablet in the morning and one in the evening. The usual duration of treatment is 6 weeks.

JORVEZA Analytical Perspective

In-depth JORVEZA Market Assessment

This report provides a detailed market assessment of JORVEZA for eosinophilic esophagitis (EoE) in the seven major markets, i.e., EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

JORVEZA Clinical Assessment

The report provides the clinical trials information of JORVEZA for EoE covering trial interventions, trial conditions, trial status, start and completion dates.

Key Questions

• What is the product type, route of administration and mechanism of action of JORVEZA?
• What is the clinical trial status of the study related to JORVEZA in eosinophilic esophagitis (EoE) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the JORVEZA development?
• What are the key designations that have been granted to JORVEZA for EoE?
• What is the forecasted market scenario of JORVEZA for EoE?
• What are the forecasted sales of JORVEZA in the seven major countries, including Europe (Germany, France, Italy, Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to JORVEZA for EoE?
• Which are the late-stage emerging therapies under development for the treatment of EoE?

Key Topics Covered:

1. Report Introduction

2. JORVEZA Overview in EoE

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical studies

2.2.2. Clinical trials information

2.2.3. Safety and efficacy

2.3. Regulatory Milestone

2.4. Other Developmental Activities

2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. JORVEZA Market Assessment

5.1. Market Outlook of JORVEZA in EoE

5.2. 5MM Analysis

5.2.1. Market Size of JORVEZA in the 5MM for EoE

5.3. Country-wise Market Analysis

5.3.1. Market Size of JORVEZA in Germany for EoE

5.3.2. Market Size of JORVEZA in France for EoE

5.3.3. Market Size of JORVEZA in Italy for EoE

5.3.4. Market Size of JORVEZA in Spain for EoE

5.3.5. Market Size of JORVEZA in the United Kingdom for EoE

6. SWOT Analysis

7. Analysts’ Views

For more information about this report visit https://www.researchandmarkets.com/r/437ylh

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900